查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1835638

嗜睡症治疗市场（按药物类别、疾病类型、年龄层和分销管道划分）—2025-2032 年全球预测

Narcolepsy Treatment Market by Drug Class, Disorder Type, Age Group, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，嗜睡症治疗市场规模将成长至 39.9 亿美元，复合年增长率为 8.06%。

主要市场统计数据
基准年2024年 21.4亿美元
预计2025年 23.1亿美元
预测年份：2032年 39.9亿美元
复合年增长率（%） 8.06%

重点介绍将发作性睡病定位为临床需求、监管进步和商业性机会交汇处的策略治疗领域

发作性睡病是一种临床上复杂的神经系统疾病，其特征是白天过度嗜睡、夜间睡眠障碍，许多患者甚至会出现猝倒。这种症状组合显着降低了生活品质和职场效率，并为诊断、长期管理和治疗方法创新带来了独特的挑战。药理学的最新进展以及对Orexin生物学理解的加深，已将发作性睡病从一种以症状为主的疾病转变为一种正在积极研究其缓解疾病机制的疾病。

在这样的临床背景下，市场参与企业面临双重任务：加速将有前景的科学方法转化为安全有效的治疗方法，同时确保患者公平获得治疗机会和永续的商业模式。生态系统正在快速发展，强调真实世界证据的生成、将药物治疗与行为和技术干预相结合的综合护理途径，以及反映长期疗效的创新定价模式。本引言强调，决策者必须在短期执行与长期投资（包括研究、伙伴关係和製造韧性）之间取得平衡，以满足患者需求和相关人员的期望。

以新机制、以病人为中心的照护和不断变化的监管预期为驱动力，改变嗜睡症治疗格局

嗜睡症的治疗模式正以多种趋同的方式改变。机制创新，尤其是调节Orexin讯号传导的努力，正在将临床焦点从症状治疗转向更精准的干预措施，这些干预措施可直接作用于核心病理学。这些科学进步与诊断途径的改进相辅相成，包括临床医生认知度的提高、客观睡眠测试的普及以及支持症状追踪和远端评估的数位工具。因此，被诊断患者的范围正在不断扩大，从而能够更早地识别出适合高级治疗方法的候选患者。

同时，付款人政策和法律规范正在不断调整，以适应新的治疗方法和基于价值的合约模式。医疗保健系统越来越重视与功能改善相关的基于结果的报销，而不仅仅是短期症状缓解。以患者为中心的护理模式也越来越受到将药物治疗与行为介入和辅助技术相结合的多学科诊所的支持。

基于证据的评估：2025 年美国关税环境将如何影响供应链、製造策略以及患者获得嗜睡症治疗的机会

贸易政策调整和关税重组正在重新审视全球医药供应链。对于嗜睡症药物而言，其影响是多方面的。跨国的活性药物原料药和关键辅料面临成本波动加剧和潜在的海关延误，这可能会影响品牌药和非专利的生产进度。製造商正在透过评估近岸外包选项、多元化供应商基础以及加快替代来源的资格认证来应对，以减轻中断的影响。这些营运响应对于维持供应连续性和避免可能对患者照护产生不利影响的库存短缺至关重要。

除了营运方面的考量之外，与关税相关的不确定性也影响整个价值链的策略规划。付款人和医疗保健提供者正在为转嫁更高采购成本的可能性做准备，并探索强调长期合约、製造商回馈以及製造商赞助的患者援助专案的筹资策略。监管机构和海关当局也面临简化基本药物进口流程的压力，相关人员越来越多地倡导对关键治疗类别实施关税豁免和加快清关途径。

策略性细分洞察揭示了治疗重点、患者群体细微差别以及与嗜睡症领域决策者相关的分布动态

细緻的细分框架阐明了临床需求、发展重点和商业管道的交集。依药物类别，我们研究了抗忧郁症、Orexin受体促效剂、羟基丁酸钠和兴奋剂，每种药物都有不同的功效和安全性以及临床定位，会影响处方模式和后续护理。按疾病类型，1 型发作性睡病和 2 型发作性睡病的不同病理和管理会影响诊断演算法、特定治疗的合格以及新药试验设计。按年龄组，成人、老年人和儿童人群之间的差异需要量身定制的给药策略、安全监测通讯协定和支援服务，以反映发展和合併症的差异。按分销管道，医院药房、线上药房和零售药房对营运、法规和病患体验有不同的影响，从依从性支援到报销工作流程。

整合这些细分视角可产生多种实际意义。治疗开发项目应将作用机制假设与主要临床表型细分相结合，以优化试验入组和有意义的终点。商业策略应区分特定管道的提案主张。医院药局管道通常强调复杂的配药和住院连续性，线上药局管道强调可近性和便利性，零售药局则支援照护现场和持续依从性。病患援助计画应根据年龄层和疾病亚型量身定制，以解决现实世界中的依从性障碍和合併症管理。最后，基于细分的证据生成，包括亚组分析和特定管道的健康经济评估，可加强付款人对话，并促进不同医疗环境中的临床应用。

关键区域分析观点了监管、医疗保健基础设施和付款人模式的地理差异如何影响发作性睡病治疗的取得和商业化。

动态变化对发作性睡病治疗的开发、核准和报销方式有重大影响。在美洲，临床实践模式和付款人结构创造了一种环境，如果有强有力的证据表明功能改善，创新就会被迅速采用，製造商通常优先考虑大规模註册和结果研究，以推进报销对话。在欧洲、中东和非洲，由于监管途径不同且医疗保健基础设施水平参差不齐，因此需要製定市场策略，强调弹性价格设定模式、与当地合作伙伴合作进行分销以及开展能力倡议倡议以提高诊断覆盖率。在亚太地区，快速的都市化、新兴市场的成长以及不同的监管预期，导致需要采取集中的国家特定采购和区域上市方法相结合的方式，优先考虑扩充性的製造和适应文化的患者支持计划。

在这些全部区域，相关人员必须协调全球开发计画和区域准入策略。协调临床试验终点与特定区域监管要求，并投资于跨区域真实世界数据收集，将加速报销和推广。此外，区域製造地与本地经销商之间的策略合作伙伴关係可以缩短重要疗法的前置作业时间，同时降低关税和海关相关风险。

关键的公司层面洞察揭示了嗜睡症生态系统中创新者、学名药製造商和服务供应商的战略态势、能力差距和伙伴关係机会

企业正透过清晰的策略选择脱颖而出。拥有专利药物的创新者通常强调整合证据项目，将对照试验与现实世界的安全性和健康结果研究相结合，以证明其高端定位的合理性。学名药生物技术公司专注于创新机制和利基适应症，并寻求伙伴关係和许可协议，以加速开发和获取药物。仿製药公司和成熟製药公司专注于规模化、经济高效的生产和可靠的分销网络，以满足对成熟疗法的需求。服务供应商和契约製造製造商将自己定位为韧性赋能者，提供供应链冗余、加速的监管提交支援和品质保证服务，以降低上市时间风险。

在开发初期，许多研发机构若能深入了解付款人参与度并建立健康经济模型，将受益匪浅，进而降低价格谈判的风险。在贸易政策趋于分化的时代，能够提供在地化能力和监管协调的製造合作伙伴将带来实际的价值。此外，投资于数位健康解决方案和患者支援平台的公司可以显着提高依从性和长期疗效，从而为付款人和临床医生创造差异化的价值提案。

产业领导者应采取指南，加速取得药物、增强供应弹性，并最大限度地发挥嗜睡症治疗的临床和商业性潜力

领导者应采取组合式方法，在短期可及性努力与机制创新和证据产生的长期投资之间取得平衡。首先，优先考虑供应链多元化和二级供应商资格认证，以降低贸易中断对企业的影响。其次，在临床计画早期纳入付款人参与和卫生经济证据开发，使临床试验终点与报销预期相一致，并支持基于价值的合约谈判。第三，投资数位化工具和整合护理模式，以增强诊断、监测依从性并捕捉对患者和付款人重要的功能性结果。

此外，企业应寻求有针对性的合作伙伴关係，将治疗专业知识与生产、监管策略和患者支持能力相结合。此类合作关係应以共担风险、加速市场准入为目标，并设定与临床和商业性目标挂钩的明确里程碑。最后，采取积极主动的政策和倡导议程，强调持续获得基本嗜睡症药物的医疗需求，并在适当情况下推广简化海关程序和关税减免。

此项分析将一手质性研究与结构化的二次证据结合，以确保获得全面、立体的观点。一手研究包括对临床医生、付款方和监管专家、製造和供应链负责人以及患者权益代表的深入访谈，以收集经验见解和营运现状。二次研究涵盖同行评审的临床文献、监管指南文件、临床试验註册中心和公共声明，以建立关于治疗机制、安全性和治疗指南的基准事实。

此分析方法将主题定性综合分析与基于情境的影响评估相结合，以评估跨细分市场和区域的策略影响。研究结果透过多位专家的最后覆核和迭代审查週期进行检验，以最大程度地减少偏差。鑑于贸易政策和持续临床开发的性质可能会迅速改变动态，本分析强调方向性洞察和策略槓桿，而非固定的预测。

将临床需求、商业策略和营运准备结合起来，为嗜睡症照护的相关人员制定一条连贯的前进道路

发作性睡病既是持续的临床挑战，也是治疗创新的动态机会。机制理解、诊断途径的改进以及支付方期望的不断变化，为能够带来显着功能改善的治疗方法创造了肥沃的土壤。然而，要实现这一潜力，需要多方面采取审慎的行动，包括产生与临床意义终点相符的强有力证据、构建能够预测贸易和关税相关影响的弹性供应链，以及协调製造商、支付方和医疗保健提供者奖励的商业模式。

总而言之，将科学严谨性、营运务实精神和积极的付款人参与相结合的相关人员，将最有可能改善患者治疗效果，并实现永续的商业性成功。这需要对研究、製造和上市能力进行协调一致的投资，并建立伙伴关係关係，以弥补能力差距，加速将创新转化为可近的医疗保健。透过果断地采取这些优先事项，申办者和医疗保健提供者能够实现为发作性睡病患者提供更好、更公平治疗的承诺。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • Pitolisant 成为首个组织胺 H3 受体拮抗剂，重塑嗜睡症市场的竞争格局
  • 推出 Solriamfetol，该药物在减少嗜睡症患者白天过度嗜睡方面表现出色
  • 个人化远端医疗追踪的整合可提高发作性睡病治疗通讯协定的依从性和疗效
  • 不断发展的数位健康平台，为嗜睡症管理提供即时症状追踪和行为矫正
  • 扩展我们的非刺激性化合物产品线，针对Orexin受体调节以外的新型神经传导物质通路
  • 製药公司与睡眠研究中心的策略合作加速了嗜睡症治疗的发展
  • 患者报告结果测量对于推动嗜睡症治疗市场进入策略的重要性日益增加

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 发作性睡病治疗市场（依药物类别）

  • 抗忧郁症
  • Orexin受体促效剂
  • 羟基丁酸钠
  • 兴奋剂

第九章 发作性睡病治疗市场（依疾病类型）

  • 1型嗜睡症
  • 2型嗜睡症

第 10 章。嗜睡症治疗市场（依年龄层）

  • 成人
  • 老年人
  • 孩子们

第 11 章。嗜睡症治疗市场（按分销管道）

  • 医院药房
  • 网路药局
  • 零售药局

第十二章 嗜睡症治疗市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 嗜睡症治疗市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 14 章。各国嗜睡症治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • AstraZeneca plc
    • Avadel Pharmaceuticals
    • Bayer AG
    • Boehringer Ingelheim GmbH
    • Cipla Limited
    • Eli Lilly and Company
    • Glenmark Pharmaceuticals Limited
    • Indivior plc
    • Jazz Pharmaceuticals plc
    • Johnson & Johnson Services, Inc.
    • Lannett Company, Inc.
    • Lupin Limited
    • Merck & Co., Inc.
    • Mylan NV by Viartis
    • NLS Pharmaceutics
    • Novartis AG
    • Pfizer Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Limited
Product Code: MRR-036C5CF3B447

The Narcolepsy Treatment Market is projected to grow by USD 3.99 billion at a CAGR of 8.06% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.14 billion
Estimated Year [2025] USD 2.31 billion
Forecast Year [2032] USD 3.99 billion
CAGR (%) 8.06%

A focused introduction that frames narcolepsy as a strategic therapeutic area where clinical need, regulatory progress, and commercial opportunity intersect

Narcolepsy remains a clinically complex neurological disorder characterized by excessive daytime sleepiness, disrupted nocturnal sleep, and, in many patients, cataplexy. This constellation of symptoms drives significant impairment in quality of life and workplace productivity, and it presents distinctive challenges for diagnosis, long-term management, and therapeutic innovation. Over recent years, advances in pharmacology and a deeper understanding of orexin biology have elevated narcolepsy from a largely symptom-managed condition to a field where disease-modifying mechanisms are being actively explored. Consequently, stakeholders across research, clinical practice, payer communities, and patient advocacy groups are recalibrating priorities to better align clinical benefit with access and affordability.

Against this clinical backdrop, market participants face a dual mandate: accelerate the translation of promising scientific approaches into safe, effective therapies while ensuring equitable patient access and sustainable commercial models. The ecosystem is evolving rapidly, with a greater emphasis on real-world evidence generation, integrated care pathways that combine pharmacotherapy with behavioral and technological interventions, and innovative pricing models that reflect long-term outcomes. For decision-makers, this introduction highlights the imperative to balance near-term operational execution with longer-term investments in research, partnerships, and manufacturing resilience to meet both patient needs and stakeholder expectations.

Transformative shifts in the narcolepsy treatment landscape driven by novel mechanisms, patient-centric care, and evolving regulatory expectations

The landscape for narcolepsy treatment is changing in several convergent ways. Mechanistic innovation, particularly efforts to modulate orexin signaling, is shifting clinical conversation from symptomatic control toward more targeted interventions that directly address core pathophysiology. These scientific advances are complemented by improvements in diagnostic pathways, including greater clinician awareness, expanded use of objective sleep testing, and digital tools that support symptom tracking and remote assessment. As a result, the profile of diagnosed patients is broadening, and earlier identification of candidates for advanced therapies is becoming feasible.

Simultaneously, payer policies and regulatory frameworks are adapting to accommodate novel therapeutic modalities and value-based contracting approaches. Health systems increasingly prioritize outcomes-driven reimbursement tied to functional gains rather than solely short-term symptom relief. Patient-centric care models are also gaining traction, with multidisciplinary clinics integrating pharmacologic treatment with behavioral interventions and assistive technologies. Taken together, these shifts create windows of opportunity for sponsors and providers to differentiate through evidence generation, patient support programs, and partnerships that streamline diagnostic-to-treatment pathways while managing real-world safety and adherence considerations.

An evidence-based appraisal of how the United States tariff environment in 2025 will influence supply chains, manufacturing strategies, and patient access for narcolepsy therapies

Trade policy adjustments and tariff realignments in 2025 are creating renewed scrutiny of global pharmaceutical supply chains. For narcolepsy therapies, the implications are multidimensional: active pharmaceutical ingredients and key excipients that cross borders face heightened cost volatility and potential customs delays, which in turn can affect production scheduling for both branded and generic formulations. Manufacturers are responding by evaluating nearshoring options, diversifying supplier bases, and accelerating qualification of alternative sources to mitigate disruption. These operational responses are essential to preserving supply continuity and avoiding inventory shortfalls that can harm patient care.

Beyond operational considerations, tariff-related uncertainty is influencing strategic planning across the value chain. Payers and providers are preparing for a potential pass-through of higher procurement costs and are exploring procurement strategies that emphasize long-term contracts, manufacturer rebates, and manufacturer-supported patient assistance programs. Regulators and customs authorities are also under pressure to streamline import processes for essential medicines, and stakeholders are increasingly advocating for tariff exemptions or rapid clearance pathways for critical therapeutic categories. In sum, the 2025 tariff environment is prompting a pragmatic shift toward supply chain resilience, contractual flexibility, and closer collaboration between manufacturers, distributors, and health systems to safeguard patient access.

Strategic segmentation insights that illuminate therapeutic priorities, patient population nuances, and distribution dynamics relevant to decision-makers in the narcolepsy space

A nuanced segmentation framework clarifies where clinical demand, development focus, and commercial channels intersect. Based on Drug Class, market study areas include Antidepressants, Orexin Receptor Agonists, Sodium Oxybate, and Stimulants, each of which carries distinct efficacy-safety profiles and clinical positioning that influence prescribing patterns and follow-up care. Based on Disorder Type, the differential presentation and management of Narcolepsy Type 1 and Narcolepsy Type 2 inform diagnostic algorithms, eligibility for specific therapeutics, and trial design considerations for novel agents. Based on Age Group, distinctions among Adults, Geriatrics, and Pediatrics require tailored dosing strategies, safety monitoring protocols, and supportive services that reflect developmental and comorbidity differences. Based on Distribution Channel, Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies present varying operational, regulatory, and patient-experience implications, from adherence support to reimbursement workflows.

Integrating these segmentation lenses yields several actionable implications. Therapeutic development programs should align mechanism-of-action hypotheses with the dominant clinical phenotype segments to optimize trial enrollment and meaningful endpoints. Commercial strategies must differentiate channel-specific value propositions: hospital pharmacy channels often center on complex dispensing and inpatient continuity, online pharmacy channels emphasize access and convenience, while retail pharmacies support point-of-care counseling and ongoing adherence. Patient support programs should be calibrated by age group and disorder subtype to address real-world adherence barriers and comorbidity management. Finally, segmentation-driven evidence generation-such as subgroup analyses and channel-specific health economic assessments-will strengthen payer dialogues and clinical uptake across diverse care settings.

Key regional perspectives that highlight how geographic differences in regulation, healthcare infrastructure, and payer models shape access and commercialization of narcolepsy treatments

Regional dynamics exert a significant influence on how narcolepsy treatments are developed, approved, and reimbursed. In the Americas, clinical practice patterns and payer structures create an environment where innovation can be rapidly adopted when supported by robust evidence of functional improvement, and manufacturers often prioritize large-scale registries and outcomes studies to inform reimbursement conversations. In Europe, Middle East & Africa, heterogeneous regulatory pathways and varying levels of healthcare infrastructure require market strategies that emphasize flexible pricing models, local partnerships for distribution, and capacity-building initiatives to improve diagnostic reach. In the Asia-Pacific region, rapid urbanization, growing specialty care networks, and differing regulatory expectations drive a mix of centralized national procurement and regional market access approaches that favor scalable manufacturing and culturally adapted patient support programs.

Across these regions, stakeholders must reconcile global development plans with localized access strategies. Harmonizing clinical trial endpoints with region-specific regulatory requirements and investing in real-world data collection across geographies will accelerate reimbursement and uptake. Moreover, regional manufacturing footprints and strategic alliances with local distributors can mitigate customs and tariff-related risks while improving lead times for critical therapies. Ultimately, a nuanced regional approach that balances global evidence generation with local market shaping will be essential to maximize therapeutic impact and facilitate sustainable patient access.

Key company-level insights that reveal strategic postures, capability gaps, and partnership opportunities across innovators, generics manufacturers, and service providers in the narcolepsy ecosystem

Companies competing or collaborating in narcolepsy are differentiating through distinct strategic choices. Innovator firms with proprietary agents often emphasize integrated evidence programs that combine controlled trials with real-world safety and health outcomes research to justify premium positioning. Specialty biotechs focus on novel mechanisms and niche indications, seeking partnerships or licensing deals to accelerate development and access. Generic and established pharmaceutical manufacturers concentrate on scale, cost-efficient manufacturing, and dependable distribution networks to meet demand for established treatments. Service providers and contract manufacturers are positioning themselves as resilience enablers, offering supply-chain redundancy, rapid regulatory filing support, and quality-assurance services that reduce time-to-market risk.

Across these company types, several capability gaps present partnership opportunities. Many developers would benefit from deeper payer-engagement expertise and health economics modeling earlier in development to de-risk pricing negotiations. Manufacturing partners that can provide localized capacity and regulatory alignment offer tangible value in an era of trade policy variability. Additionally, firms investing in digital health solutions and patient-support platforms can materially improve adherence and long-term outcomes, creating differentiated value propositions for payers and clinicians. Strategic alliances that combine therapeutic innovation with scale manufacturing, market access acumen, and digital adherence tools will likely define the next wave of successful commercialization efforts.

Actionable recommendations for industry leaders to accelerate access, strengthen supply resilience, and maximize the clinical and commercial potential of narcolepsy therapies

Industry leaders should adopt a portfolio approach that balances near-term access initiatives with longer-term investments in mechanistic innovation and evidence generation. First, prioritize supply-chain diversification and qualification of secondary suppliers for critical inputs to reduce vulnerability to trade disruptions, while also exploring regional manufacturing partnerships to shorten delivery timelines. Second, embed payer engagement and health economic evidence development early in clinical programs to align trial endpoints with reimbursement expectations and to support value-based contracting discussions. Third, invest in digital tools and integrated care models that enhance diagnosis, monitor adherence, and capture functional outcomes that matter to patients and payers.

Additionally, companies should pursue targeted collaborations that pair therapeutic expertise with capabilities in manufacturing, regulatory strategy, and patient support. These alliances should be structured to share risk and accelerate market entry, with clear milestones tied to clinical and commercial objectives. Finally, adopt a proactive policy and advocacy agenda that emphasizes the medical necessity of uninterrupted access to essential narcolepsy therapies, promoting streamlined customs procedures and tariff exemptions where appropriate. Taken together, these recommendations provide a pragmatic roadmap to improve patient outcomes while safeguarding

Transparent research methodology describing sources, analytic approaches, and validation procedures used to ensure the reliability and relevance of narcolepsy market insights

This analysis synthesizes primary qualitative research and structured secondary evidence to ensure a comprehensive, triangulated perspective. Primary research included in-depth interviews with clinicians, payers, regulatory specialists, manufacturing and supply-chain leaders, and patient advocacy representatives to capture experiential insights and operational realities. Secondary research encompassed peer-reviewed clinical literature, regulatory guidance documents, clinical trial registries, and public policy statements to establish a factual baseline for therapeutic mechanisms, safety profiles, and treatment guidelines. Data from treatment registries and health-system protocols were reviewed where available to contextualize real-world practice patterns.

Analytic methods combined thematic qualitative synthesis with scenario-based impact assessment to evaluate strategic implications across segmentation and regions. Findings were validated through cross-checks with multiple expert respondents and iterative review cycles to minimize bias. Limitations are acknowledged: the evolving nature of trade policy and ongoing clinical development can alter dynamics rapidly, and therefore the analysis emphasizes directional insights and strategic levers rather than fixed projections. Where applicable, potential data gaps are highlighted, and recommended follow-up research steps are provided to support deeper, program-specific decision-making.

Concluding synthesis that connects clinical needs, commercial strategy, and operational readiness to chart a coherent path forward for stakeholders in narcolepsy care

Narcolepsy represents both a persistent clinical challenge and a dynamic opportunity for therapeutic innovation. The convergence of mechanistic science, improved diagnostic pathways, and evolving payer expectations creates fertile ground for therapies that deliver meaningful functional improvement. However, realizing that potential requires deliberate action across multiple domains: robust evidence generation tailored to clinically meaningful endpoints, resilient supply chains that anticipate trade and tariff-related disruptions, and commercial models that align incentives across manufacturers, payers, and providers. Patient-centered approaches, including digital monitoring and targeted support services, will be essential to translate pharmacologic advances into durable real-world benefits.

In conclusion, stakeholders who integrate scientific rigor with operational pragmatism and proactive payer engagement will be best positioned to improve patient outcomes while achieving sustainable commercial success. The path forward involves coordinated investment in research, manufacturing, and market access capabilities, alongside partnerships that bridge capability gaps and accelerate the translation of innovation into accessible care. By acting decisively on these priorities, sponsors and providers can deliver on the promise of better, more equitable care for people living with narcolepsy.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advent of pitolisant as first histamine H3 receptor antagonist reshaping competitive dynamics in the narcolepsy market
  • 5.2. Emergence of solriamfetol demonstrating superior efficacy in reducing excessive daytime sleepiness among narcolepsy patients
  • 5.3. Integration of personalized telemedicine follow-up improving adherence and outcomes in narcolepsy treatment protocols
  • 5.4. Growth of digital health platforms offering real-time symptom tracking and behavior modification for narcolepsy management
  • 5.5. Expansion of non-stimulant pipeline compounds targeting novel neurotransmitter pathways beyond orexin receptor modulation
  • 5.6. Strategic collaborations between pharmaceutical firms and sleep research centers accelerating narcolepsy drug development
  • 5.7. Increasing emphasis on patient-reported outcome measures driving market access strategies for narcolepsy therapies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Narcolepsy Treatment Market, by Drug Class

  • 8.1. Antidepressants
  • 8.2. Orexin Receptor Agonists
  • 8.3. Sodium Oxybate
  • 8.4. Stimulants

9. Narcolepsy Treatment Market, by Disorder Type

  • 9.1. Narcolepsy Type 1
  • 9.2. Narcolepsy Type 2

10. Narcolepsy Treatment Market, by Age Group

  • 10.1. Adults
  • 10.2. Geriatrics
  • 10.3. Pediatrics

11. Narcolepsy Treatment Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Narcolepsy Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Narcolepsy Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Narcolepsy Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. AstraZeneca plc
    • 15.3.2. Avadel Pharmaceuticals
    • 15.3.3. Bayer AG
    • 15.3.4. Boehringer Ingelheim GmbH
    • 15.3.5. Cipla Limited
    • 15.3.6. Eli Lilly and Company
    • 15.3.7. Glenmark Pharmaceuticals Limited
    • 15.3.8. Indivior plc
    • 15.3.9. Jazz Pharmaceuticals plc
    • 15.3.10. Johnson & Johnson Services, Inc.
    • 15.3.11. Lannett Company, Inc.
    • 15.3.12. Lupin Limited
    • 15.3.13. Merck & Co., Inc.
    • 15.3.14. Mylan N.V. by Viartis
    • 15.3.15. NLS Pharmaceutics
    • 15.3.16. Novartis AG
    • 15.3.17. Pfizer Inc.
    • 15.3.18. Sun Pharmaceutical Industries Ltd.
    • 15.3.19. Takeda Pharmaceutical Company Limited
    • 15.3.20. Teva Pharmaceutical Industries Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS NARCOLEPSY TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NARCOLEPSY TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. NARCOLEPSY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NARCOLEPSY TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY OREXIN RECEPTOR AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY OREXIN RECEPTOR AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY OREXIN RECEPTOR AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY OREXIN RECEPTOR AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY OREXIN RECEPTOR AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY OREXIN RECEPTOR AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY SODIUM OXYBATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY SODIUM OXYBATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY SODIUM OXYBATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY SODIUM OXYBATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY SODIUM OXYBATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY SODIUM OXYBATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY STIMULANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY STIMULANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY STIMULANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY STIMULANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY STIMULANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY STIMULANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY NARCOLEPSY TYPE 1, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY NARCOLEPSY TYPE 1, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY NARCOLEPSY TYPE 1, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY NARCOLEPSY TYPE 1, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY NARCOLEPSY TYPE 1, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY NARCOLEPSY TYPE 1, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY NARCOLEPSY TYPE 2, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY NARCOLEPSY TYPE 2, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY NARCOLEPSY TYPE 2, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY NARCOLEPSY TYPE 2, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY NARCOLEPSY TYPE 2, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY NARCOLEPSY TYPE 2, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY GERIATRICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY GERIATRICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY GERIATRICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY GERIATRICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY GERIATRICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY PEDIATRICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY PEDIATRICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. AMERICAS NARCOLEPSY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 88. AMERICAS NARCOLEPSY TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 89. AMERICAS NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 90. AMERICAS NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 91. AMERICAS NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 92. AMERICAS NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 93. AMERICAS NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. AMERICAS NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. AMERICAS NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 96. AMERICAS NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. NORTH AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 100. NORTH AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 102. NORTH AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. NORTH AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 106. NORTH AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. LATIN AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 110. LATIN AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 112. LATIN AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. LATIN AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 116. LATIN AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 127. EUROPE NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. EUROPE NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. EUROPE NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 130. EUROPE NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 131. EUROPE NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. EUROPE NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 133. EUROPE NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. EUROPE NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. EUROPE NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 136. EUROPE NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. MIDDLE EAST NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 140. MIDDLE EAST NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 142. MIDDLE EAST NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. MIDDLE EAST NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 146. MIDDLE EAST NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 147. AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 150. AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 151. AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 156. AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. ASEAN NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. ASEAN NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. ASEAN NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 172. ASEAN NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 173. ASEAN NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. ASEAN NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. ASEAN NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. ASEAN NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. ASEAN NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 178. ASEAN NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 179. GCC NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GCC NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GCC NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 182. GCC NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 183. GCC NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. GCC NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. GCC NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GCC NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GCC NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 188. GCC NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPEAN UNION NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPEAN UNION NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPEAN UNION NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPEAN UNION NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPEAN UNION NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 199. BRICS NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. BRICS NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. BRICS NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 202. BRICS NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 203. BRICS NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. BRICS NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. BRICS NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. BRICS NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. BRICS NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 208. BRICS NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 209. G7 NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. G7 NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. G7 NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 212. G7 NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 213. G7 NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. G7 NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. G7 NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. G7 NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. G7 NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 218. G7 NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 219. NATO NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. NATO NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. NATO NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 222. NATO NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 223. NATO NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. NATO NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. NATO NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. NATO NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. NATO NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 228. NATO NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. UNITED STATES NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 232. UNITED STATES NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 233. UNITED STATES NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. UNITED STATES NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. UNITED STATES NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. UNITED STATES NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. UNITED STATES NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. UNITED STATES NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. CANADA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 240. CANADA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 241. CANADA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. CANADA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. CANADA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. CANADA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. CANADA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. CANADA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. MEXICO NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 248. MEXICO NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 249. MEXICO NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. MEXICO NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. MEXICO NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. MEXICO NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. MEXICO NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. MEXICO NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. BRAZIL NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 256. BRAZIL NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 257. BRAZIL NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. BRAZIL NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. BRAZIL NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. BRAZIL NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. BRAZIL NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. BRAZIL NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. UNITED KINGDOM NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 264. UNITED KINGDOM NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 265. UNITED KINGDOM NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. UNITED KINGDOM NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. UNITED KINGDOM NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. UNITED KINGDOM NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. UNITED KINGDOM NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. UNITED KINGDOM NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 271. GERMANY NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 272. GERMANY NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 273. GERMANY NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. GERMANY NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. GERMANY NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GERMANY NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GERMANY NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 278. GERMANY NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 279. FRANCE NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 280. FRANCE NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 281. FRANCE NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. FRANCE NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. FRANCE NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. FRANCE NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. FRANCE NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 286. FRANCE NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 287. RUSSIA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 288. RUSSIA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 289. RUSSIA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. RUSSIA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. RUSSIA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 292. RUSSIA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 293. RUSSIA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 294. RUSSIA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 295. ITALY NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 296. ITALY NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 297. ITALY NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. ITALY NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. ITALY NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 300. ITALY NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 301. ITALY NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 302. ITALY NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 303. SPAIN NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 304. SPAIN NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 305. SPAIN NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. SPAIN NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. SPAIN NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 308. SPAIN NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 309. SPAIN NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 310. SPAIN NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 311. CHINA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 312. CHINA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 313. CHINA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. CHINA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. CHINA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 316. CHINA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 317. CHINA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 318. CHINA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 319. INDIA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 320. INDIA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 321. INDIA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. INDIA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 323. INDIA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 324. INDIA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 325. INDIA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 326. INDIA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 327. JAPAN NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 328. JAPAN NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 329. JAPAN NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 330. JAPAN NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 331. JAPAN NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 332. JAPAN NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 333. JAPAN NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 334. JAPAN NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 335. AUSTRALIA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 336. AUSTRALIA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 337. AUSTRALIA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 338. AUSTRALIA NARCOLEPSY TREATM